Sinclair Pharma PLC (LON:SPH) insider Chris Spooner acquired 200,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was purchased at an average cost of GBX 23 ($0.31) per share, for a total transaction of £46,000 ($62,381.34).
Sinclair Pharma PLC (LON SPH) traded down GBX 0.10 ($0.00) during midday trading on Tuesday, hitting GBX 23.05 ($0.31). 669,980 shares of the company were exchanged, compared to its average volume of 181,789. The stock has a market cap of $113.23 and a P/E ratio of -768.33. Sinclair Pharma PLC has a 1 year low of GBX 21 ($0.28) and a 1 year high of GBX 36.35 ($0.49).
A number of research firms recently commented on SPH. Peel Hunt reaffirmed a “buy” rating and issued a GBX 68 ($0.92) target price on shares of Sinclair Pharma in a research report on Monday, October 23rd. N+1 Singer reaffirmed a “buy” rating and issued a GBX 37 ($0.50) target price on shares of Sinclair Pharma in a research report on Tuesday, September 19th. Jefferies Group reaffirmed a “buy” rating and issued a GBX 55 ($0.75) target price on shares of Sinclair Pharma in a research report on Friday, September 29th. Finally, Numis Securities reaffirmed a “hold” rating and issued a GBX 21 ($0.28) target price on shares of Sinclair Pharma in a research report on Tuesday. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Sinclair Pharma has a consensus rating of “Buy” and an average price target of GBX 50.40 ($0.68).
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma and related companies with MarketBeat.com's FREE daily email newsletter.